NEW YORK, November 4, 2016 /PRNewswire/ --
Today, Stock-Callers.com is covering the highly fragmented global MedicalAppliances and Equipment space which is expected to reach approximately $302 billion in 2017 with a CAGR of 6.1% during the period of 2011 to 2017. Equities to assess today are: EnteroMedics Inc. (NASDAQ: ETRM), Amedica
St. Paul, Minnesota headquartered EnteroMedics Inc.'s shares saw a decline of 6.35% and finished Thursday's trading session at $0.08 with a total trading volume of 3.10 million shares. The stock is trading below its 50-day moving average by 38.41%. Shares of the Company, which focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders, have a Relative Strength Index (RSI) of 34.55.
As per notes filed with the SEC, on November 1st, 2016, EnteroMedics announced that as of November 1st, 2016, there were 91,375,309 shares of its common stock issued and outstanding, an increase of 21,679,150 shares since September 14th, 2016, the last date for which the Company had publically announced its issued an outstanding share count. The increase in the Company's share count is a result of the conversion or acceleration of outstanding principal and interest amounts of its outstanding 7.0% senior amortizing convertible notes by the holders of the Notes. Sign up and read the free research report on ETRM at:
On Thursday, shares in Salt Lake City, Utah headquartered Amedica Corp. recorded a trading volume of 571,184 shares, and ended the session 7.27% lower at $0.63. The stock is trading 28.07% below its 50-day moving average. Shares of the Company, which develops, manufactures, and sells a range of medical devices based on its silicon nitride ceramic technology platform in the US, Europe, and South America, have an RSI of 26.80.
On October 28th, 2016, Amedica announced that it will release financial results for Q3 2016 on November 10th, 2016, after the market closes. Following the release, on the same day, the Company will host a conference call and simultaneous audio webcast with Dr. Sonny Bal, Amedica's Chairman and CEO, to review its Q3 2016 financial results at 5:00 p.m. ET. The complimentary research report on AMDA can be downloaded at:
Shares in Richmond, Canada headquartered Neovasc Inc. closed the day at $0.54, down 16.73%. The stock recorded a trading volume of 2.46 million shares, which was above its three months average volume of 1.58 million shares. The Company's shares have gained 7.44% in the last one month, and are trading 4.20% below their 50-day moving average. Additionally, shares of Neovasc, which develops, manufactures, and markets cardiovascular products worldwide, have an RSI of 46.45.
On November 01st, 2016, Neovasc reported the findings of the Federal District Court regarding several post-trial motions stemming from a trial jury's verdict in May 2016. CardiAQ filed suit against Neovasc in the US District Court for the District of Massachusetts in 2014. In the order, Judge Allison D. Burroughs ruled in favor of CardiAQ on the issue of inventorship of Neovasc's '964 Patent. At the same time, the judge denied CardiAQ's motion for an injunction that would have shut down the development of Tiara™, thus allowing Neovasc to continue development and commercialization of Tiara™, while also denying Neovasc's motions for a new trial. Judge Burroughs upheld the jury's verdict and US$70 million award against Neovasc, and awarded US$21 million in enhanced damages to that award. Register for free on Stock-Callers.com and access the latest report on NVCN at:
At the closing bell yesterday, shares in San Diego, California headquartered ResMed Inc. ended 0.36% lower at $57.34 and with a total trading volume of 617,793 shares. The stock has advanced 8.43% on an YTD basis. The Company's shares are trading below their 200-day moving average by 6.24%. Furthermore, shares of ResMed, which designs, develops, manufactures, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders, have an RSI of 22.17.
On October 04th, 2016, research firm JP Morgan initiated a 'Neutral' rating on the Company's stock, issuing a target price of $64 per share.
On November 01st, 2016, ResMed introduced the AirFit N20 nasal mask and AirFit F20 full face mask for positive airway pressure (PAP) treatment of sleep apnea. The AirFit N20 and AirFit F20 feature ResMed's innovative new InfinitySeal silicone cushion that adapts to the unique facial contours of each patient to increase comfort, improve fit and reduce leakage for maximum treatment efficacy. ResMed claimed that the AirFit N20 fit 99% of patients tested, and the AirFit F20 fit 97%, regardless of facial structure, gender or age. Get free access to your research report on RMD at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Morris Capital Inc
Subscribe to our Free Newsletters!
Steroids are miracle drugs but have to be used with caution. Some steroids are illegal to use, ...
Abruptio placenta is a serious but rare complication of pregnancy where a separation of placenta ...
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...View All